Outcome Capital - Strategic Life Sciences Investment Banking

Creating outcomes like no other. Maximizing your company’s value…

Unique Insights

In-Depth Industry Experience & Networks

Personal Commitment to Clients

Exceptional Record of Success

Community

About Outcome Life Sciences Pulse

Outcome Capital Named Top Life Sceneces Investement Banking Firm 2025 by Life Science Review

January 2025
Read More
From inception, and through clinical and commercial development, the Outcome Capital team were true partners and collaborators, playing a pivotal strategic role in positioning the company and facilitating multiple financing events as well as a clear path to a liquidity event. Their work culminated in an exit transaction for the benefit of shareholders and patients, I cannot thank them enough.

Patrick Green President, Elios Vision
Outcome Capital has won honors as the Top Life Sciences Advisory & Investment Banking Firm – 2024 per Life Sciences Magazine

January 2024

Read More
Outcome Capital as one of the Top 10 Life Science Financial Service Providers 2023

July 20, 2023

Read More
Driven to create value for our clients to secure the best possible outcome

The added value Outcome Capital was responsible for was 10 times greater than the value we invested in their services. Our only regret was in not bringing them on sooner.

John D Green, MD CEO, Advanced Uro-Solutions
An Outcome professional served as lead banker in the sale of Annese & Associates. His knowledge of our industry, extensive contacts within it, and attention to all facets of the transaction proved invaluable. His care and commitment to the Annese shareholders, board, myself and by extension to all of our employees was simply outstanding.

Ray Apy CEO, Annese & Associates
The diversity of backgrounds enables Outcome to offer deep understanding and unique insights

The Outcome team got fully up to speed with all aspects of our technology and business, and could pitch our company’s story, and value proposition, as well as anyone. They researched a full list of potential acquirers in order to target those with high potential, and articulate the true value proposition for each target in very clear terms.

Victor Esch, PhD President & CEO, DNAe
Outcome Capital’s knowledge and expertise were crucial in bringing this transaction to fruition. Outcome advised us on both the acquisition and the financing and exceeded all our expectations.

Rolf Purzer CEO, ATPCO
A true partner and collaborator

Outcome Capital was a true partner and collaborator starting from the evaluation and sourcing phase. Their teamwork and attention to detail was perfectly accompanied by their knowledge and expertise with the industry segment. Furthermore, their diligence prep rigor was extremely useful once we got to the post term-sheet/closing phase of the transaction. I could not have survived this transaction without their help.

Rohit Nayak CEO, Electronic Registry Systems
In-depth industry knowledge & networks

I was impressed by Outcome Capital’s thoughtful M&A strategy and process, which stemmed from their ability to capture the complexities of Beryllium’s scientific and business value propositions.

Johan Pontin CEO, Beryllium Discovery
The Outcome Capital team was a committed and flexible partner that proved critical to a successful acquisition.

Mahfuz Ahmed CEO, DISYS
Passionately working for our clients' success

I have worked with Outcome Capital on multiple, complex transactions. They bring strategic insights and operational experience to the table like no other investment bankers I have ever worked with.

Lisa Dunlea CEO, XableCath
I knew Outcome by reputation, and they were the only group I felt comfortable engaging with and trusting with this deal. What they provided exceeded my expectations not only in value, but also in their conduct and earnestness. It was a pleasure doing business with Outcome Capital.

Andrew Ferrara Chairman, Boston Healthcare Associates
I thank the Outcome team for driving the Verrix acquisition to completion, for protecting our interests and for an excellent job in navigating the bumps along the way. The Outcome team ran a solid competitive process that caused the market to speak toward a transaction for the benefit of both buyer and seller.

Sami El-Saden Chairman and CEO, Verrix
We cannot thank you enough. We appreciate your guidance, expertise, candor, and the fact that you really care. What a great way to do business.

William Peterson Founder & Director, Propella Therapeutics

Transactions

Has merged with

Has been acquired by

Completed Series C Financing

has sold its assets to

has acquired the assets of

has received a minority investment from

$175 Million

Has been acquired by

Has been acquired by

$32 Million

Has Completed a Growth Equity Financing

Has Completed an Oversubscribed Growth Equity Round

Received an equity investment from

Has sold its business to

Has Acquired

$120 Million

Has Sold Its Business To

$15,000,000

Has Issued 5,000,000 Shares of Series A Preferred Stock

Has been acquired by

Has been acquired by an Undisclosed Family Office

Received an equity investment from

Capital Raise

Has sold its business to

Has Sold its Energy Management Business to

Has Sold Its Smart Grid Solutions Business To

View More Transactions

News July 08, 2025

Outcome Capital Launches the First Dedicated Ophthalmology Practice to Address the World’s Leading Cause of Disability

Appoints Paul Ryb Managing Director to Lead Firm’s Expansion BOSTON–(BUSINESS WIRE)-July 8, 2025-Outcome Capital, LLC, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that Paul Ryb has been appointed Managing Director and will lead the firm’s dedicated ophthalmology practice, providing strategic guidance, transactional support, and advisory services to clients […]

Outcome Capital Life Science Market Pulse, May 2025

Outcome Capital Life Science Market Pulse May 2025 Click to view our LifeSciences Pulse Newsletter

Download

Contact Us for More Information

Would you like to learn more about working with Outcome Capital or discuss your specific needs?

Life Sciences

Healthcare

View Our Monthly Newsletter

Unique Insights

In-Depth Industry Experience & Networks

Personal Commitment to Clients

Exceptional Record of Success

Community

Outcome Capital Named Top Life Sceneces Investement Banking Firm 2025 by Life Science Review

Patrick Green President, Elios Vision

Outcome Capital has won honors as the Top Life Sciences Advisory & Investment Banking Firm – 2024 per Life Sciences Magazine

Outcome Capital as one of the Top 10 Life Science Financial Service Providers 2023

Driven to create value for our clients to secure the best possible outcome

John D Green, MD CEO, Advanced Uro-Solutions

Ray Apy CEO, Annese & Associates

The diversity of backgrounds enables Outcome to offer deep understanding and unique insights

Victor Esch, PhD President & CEO, DNAe

Rolf Purzer CEO, ATPCO

A true partner and collaborator

Rohit Nayak CEO, Electronic Registry Systems

In-depth industry knowledge & networks

Johan Pontin CEO, Beryllium Discovery

Mahfuz Ahmed CEO, DISYS

Passionately working for our clients' success

Lisa Dunlea CEO, XableCath

Andrew Ferrara Chairman, Boston Healthcare Associates

Sami El-Saden Chairman and CEO, Verrix

William Peterson Founder & Director, Propella Therapeutics

News July 08, 2025

Outcome Capital Launches the First Dedicated Ophthalmology Practice to Address the World’s Leading Cause of Disability

Resources May 2025

Outcome Capital Life Science Market Pulse, May 2025